2016 Webinars
Collapse Bacterial and Fungal Typing by Sequence-based Methods

Please note that this webinar was recorded in 2016. All AMPEDTM content is reviewed and approved annually by the Training & Education Committee as relevant and accurate, but new data may now be available and new studies may have since been published.

AMP Education is constantly updating these educational offerings, so keep checking back at educate.amp.org for new content, content updates, and information on cutting-edge molecular pathology research and applications.


Description:

This presentation discusses current methods used to identify bacteria by 16S rRNA gene sequencing and fungi by use of the ITS (Internal Transcribed Spacers) and D1/D2 regions, including both technical and bioinformatic analyses. Additional content covers use of these methods to identify pathogens in primary samples, example cases and clinical reporting, potential application of next generation sequencing (NGS)-based methods, and considerations for labs developing and implemeting these assays.

Speaker: Lynn Bry, MD, PhD

Host: Colleen Kraft, MD

Duration: 40 min.

Level of Instruction: Intermediate


You might also be interested in:

All sales are final. No refunds will be issued.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

Formats Available: Bry Presentation
Original Course Date: May 27, 2016
MORE INFOMORE INFO Bacterial and Fungal Typing by Sequence-based Methods
Collapse Promises and Pitfalls of Circulating Tumor DNA

Please note that this webinar was recorded in 2016. All AMPEDTM content is reviewed and approved annually by the Training & Education Committee as relevant and accurate, but new data may now be available and new studies may have since been published.

AMP Education is constantly updating these educational offerings, so keep checking back at educate.amp.org for new content, content updates, and information on cutting-edge molecular pathology research and applications.


In oncology, there are a variety of potential clinical applications for a minimally invasive blood test for DNA released from tumor cells. Such applications include detecting early stage disease, tracking response to therapy, prompt identification of disease relapse or recurrence, and recognition of clonal evolution.  Numerous small-scale studies have demonstrated that quantitation of mutations in circulating tumor DNA (ctDNA) is feasible from the blood of cancer patients. The increased adoption of targeted cancer therapies underscores the need to augment invasive tissue biopsies with alternative detection methods that rapidly monitor treatment response. Although most studies have been proof of principle, ctDNA methods hold great promise in cancer diagnostics.

 

Speaker: Christina Lockwood, PhD, DABCC, FACB

Duration: 1.0 hr

Level of Instruction: Intermediate


You might also be interested in:

All sales are final. No refunds will be issued.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

Formats Available: Streaming
Original Course Date: June 09, 2016
MORE INFOMORE INFO Promises and Pitfalls of Circulating Tumor DNA
Collapse Structural Variant Discovery and Considerations for the Clinical Laboratory

Please note that this webinar was recorded in 2016. All AMPEDTM content is reviewed and approved annually by the Training & Education Committee as relevant and accurate, but new data may now be available and new studies may have since been published.

AMP Education is constantly updating these educational offerings, so keep checking back at educate.amp.org for new content, content updates, and information on cutting-edge molecular pathology research and applications.


Description:

In this webinar, Dr. Zehir talks about the structural variation in the genome and the ways it relates to disease formation and treatment. He focuses on the different strategies to detect and visualize them using next-generation sequencing technologies for the clinical laboratory with a focus in cancer. 


Speaker: Ahmet Zehir, PhD

Host: N. Sertac Kip, MD, PhD

Duration: 40 min.

Level of Instruction: Advanced


You might also be interested in:

All sales are final. No refunds will be issued.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

Formats Available: Zehir Presentation
Original Course Date: September 09, 2016
MORE INFOMORE INFO Structural Variant Discovery and Considerations for the Clinical Laboratory
Collapse The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer

Please note that this webinar was recorded in 2016. All AMPEDTM content is reviewed and approved annually by the Training & Education Committee as relevant and accurate, but new data may now be available and new studies may have since been published.

AMP Education is constantly updating these educational offerings, so keep checking back at educate.amp.org for new content, content updates, and information on cutting-edge molecular pathology research and applications.


Recent definitions for clinical utility of molecular tests focus on whether a test result will alter treatment. This definition neglects other uses of molecular testing to diagnose disease, manage symptoms, prognosticate or predict future disease. The fullest realization of precision medicine will require embracing all aspects of clinical utility. This three-part webinar series, supported by AMP, presents the discussions of AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility (FEND) working group, and its resulting publication, “The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology” (Joseph L, et al. J Mol Diagn. 2016;18[5]:605–619).

 

Part 1 - An Overview of AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility

Speakers: Loren Joseph, MD; Elaine Lyon, PhD

Host: Roger Klein, MD, JD

 

Part 2 - AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility – Oncology Cases

Speakers: Pranil Chandra, DO, FCAP, FASP; Rajyasree Emmadi, MD, FCAP

Host: Loren Joseph, MD

 

Part 3: AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility – Inherited Conditions

Speakers: Stephanie Hallam, PhD, FACMG, MBA; Victoria Pratt, PhD, FACMG

Host: Elaine Lyon, PhD

Practice Guideline Available Here

Total Duration: 3 hr

Level of Instruction: Advanced

 

You might also be interested in:

All sales are final. No refunds will be issued.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

Formats Available: Streaming
Original Course Date: September 28, 2016
MORE INFOMORE INFO The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer